Samarpan Majumder, M.S., Ph.D.
Department of Genetics Office: Stanley S Scott Cancer Center 1700 Tulane Avenue, Rm# 906 New Orleans, LA 70112 Ph# 504-210-2670 E.Mail: email@example.com
Department of Genetics
Office: Stanley S Scott Cancer Center
1700 Tulane Avenue, Rm# 906
New Orleans, LA 70112
Ph.D (Biochemistry) Calcutta University, Calcutta, India (awarded 2000)
Dr. Majumder joined the Department of Genetics at LSUHSC in November 2017 after spending 18 years in acdemia and biotech industries. Dr. Majumder came to the University of North Carolina (UNC) at Chapel Hill as a postdoctoral fellow just after submitting his PhD thesis and worked in the field of Drosophila genetics. He was Instrumental in finding a novel gene (mei9) in fruit fly, drosophila, that is involved in nucleotide excision repair (NER). In 2003, he joined at Lineberger Comprehensive Research Center in UNC and worked in prostate cancer research. While working in this field, he A) Documented the importance of breast cancer gene, her2, in the late stage of prostate cancer progression. B) Identified the involvement of Coactivator Associated Arginine Methyltransferase (CARM1) and the importance of epigenetics in prostate cancer progression and C) contributed to implicate Ack1, a growth promoting cellular protein, in late stage of prostate cancer. From 2006 to 2009, he worked with Prof. Bryan Roth at Dept. of Pharmacology in UNC and was actively involved in National Institute of Mental Health's (NIMH) psychoactive drug discovery program. He Collaborated with University of Wisconsin at Milwaukee and screened compounds that resulted in some peer reviewed publications (5) and compounds with high therapeutic potentials.
In 2009, Dr. Majumder accepted an offer from an early stage biopharmaceutical company, Vascular Pharmaceutical, NC,and, joined there as Director-Preclinical Development. In this capacity, he was responsible in guiding A) Vascular's day to day research activities comprising of a team of researchers (3) in their effort to design, develop and commercialize a novel antibody against diabetes accelerated heart complications and B) Successfully coordinated preclinical studies in pigs to validate the efficacy of in-house monoclonal antibody.
From 2012 to 2016, Dr. Majumder worked as a Sr. Scientist in another biotech company, Novametics, NC, and led company's effort to develop and commercialize a novel dignostic assay kit to detect blood clotting disorders. Dr. Majumder successfully A) validated and optimized a novel diagnostic clotting assay with a patented component to detect blood coagulation disorders. B) Collaborated with senior management and cross-functional stakeholders to enable selection of appropriate assay platform and formulation of kits. C) Manage a team of cross functional scientists (up to 5) from various disciplines to ensure that all timelines and project deliverables were met. He was in charge of Novametics scientific execution and played an important role in company's strategy and business development. D) Worked with subject matter expert (SME) to facilitate the clinical trial of patient samples at Duke and UNC.and E) Positioned the company into a "sweetspot" for a licensing agreement with big healthcare companies.
Dr. Majumder has been recruited in this department to bolster department's strong focus on Cancer Research, and specifically, breast cancer program. He will bring in his valuable experience in industry and his previous translational research experience in cancer to integrate and navigate a few ongoing breast cancer research projects. As a coinvestigator, he will cooperate, collaborate, write and submit grants with Prof. Lucio Miele's future focus on A) antibody based therapy in Triple Negative Breast Cancer (TNBC). Dr. Majumder will participate in additional B) preclinical animal study to see the potency and efficacy of an Investigational New Drug (IND) for primary and metastatic NOTCH+ breast cancer patients in collaboration with another pharmaceutical company. He will be C) taking participation in another study to investigate the clinical benifit of a novel orally available small molecule compound over the existing one in the market for hormone refractory ER+ and HER2- metastatic breast cancer in postmenopausal women in collaboration with Xavier University for a potential future DOD and/or SBIR phase II grant application. He is keen to study the intestinal microbiome and it's potential impact in PDX breast cancer model of mouse treated with checkpoint inhibitors (cancer immunotherapy).
In near future, he will also participate in teaching activities
|Committees & Administrative Responsibilities||
Dr. Majumder is exited to be participating in various other departmental committees as and when required.